Three Year Anniversary of Listing

On August 24, 2020, with the bell ringing at the Shenzhen Stock Exchange, CONTEC Medical System (Qinhuangdao) Co., Ltd. officially listed on the ChiNext, becoming the first listed company in Hebei Province under the ChiNext registration system, marking the beginning of a new chapter.

 

As a high-tech enterprise specializing in the research and development, production, and sales of medical diagnostics and monitoring equipment, CONTEC founded in 1996, has been following the tide of the times. Focusing on the development of its core business, it has taken steady steps, enhancing its research and development and innovation capabilities. With a growing product portfolio, an independent and controllable complete industry chain, and a global marketing network, the company has achieved the status of being one of the largest medical device production and research bases in northern China. Its products, known for their high cost-effectiveness and quality, have been sold to more than 150 countries and regions worldwide.

 

Over the past three years, in the face of global uncertainties such as the pandemic and international challenges, the company has maintained a strategic focus on long-term development. It has continuously strengthened research and development innovation, diversified its medical equipment product line, explored domestic and international markets, and deepened its omni-channel marketing system integrating online and offline channels. The company has accelerated the construction of an intelligent manufacturing system, strengthened its vertical integration competitiveness in the industry chain, and strived to make its core business more refined, superior, and stronger. Like a tree deeply rooted in the soil, it remains resilient, unafraid of storms, growing downwards with roots and upwards with branches, enhancing development resilience and internal dynamics, laying a solid foundation for the company's sustainable development.

 

CONTEC Medical has formed a professional and well-structured research and development team with outstanding research capabilities, supporting the company's development strategy and business layout in terms of both breadth and depth. With headquarters in the north, and subsidiaries in Changsha and Shenzhen, the company has established a research and development layout resembling one axis and two wings in China. This enables the company to maintain a continuous stream of independent innovation in the intense market competition. As of the end of 2022, the company holds 370 domestic and foreign patents, 217 software copyrights, and has obtained 92 domestic and foreign medical device market access permits.